School of Environmental and Chemical Engineering, Shanghai University, Shanghai 200444, China.
Department of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR, China.
Int J Pharm. 2024 Jun 25;659:124202. doi: 10.1016/j.ijpharm.2024.124202. Epub 2024 May 4.
Photodynamic therapy (PDT) shows great potential in precision tumor treatment. However, its efficacy is inhibited by the antioxidant defense capacities of tumor cells. To address this challenge, a near-infrared light-controlled nanosystem (UCNPs@mSiO@Azo@ZnPc&BBM, PB@UA) was developed using emission-switchable upconversion nanoparticles (UCNPs) to independently and precisely control the release of berbamine (BBM) and activation of photosensitizer for enhanced PDT in deep tissues. Firstly, BBM release was triggered by exciting PB@UA at 980 nm. The BBM could inhibit the activities of antioxidant enzymes and disrupt calcium ion regulation, making the tumor cells more susceptible to ROS-induced cell death in the following PDT treatment. The PDT was initiated by irradiating the photosensitizers of ZnPc on PB@UA at 808 nm and achieved a tumor inhibition rate of 80.91 % in vivo, which is significantly higher than that of unique PDT (31.78 %) or BBM (11.29 %) treatment and demonstrates the potential of our strategy for improved cancer treatment.
光动力疗法（PDT）在精准肿瘤治疗中具有巨大的潜力。然而，其疗效受到肿瘤细胞抗氧化防御能力的抑制。为了解决这一挑战，开发了一种近红外光控纳米系统（UCNPs@mSiO@Azo@ZnPc&BBM，PB@UA），该系统使用发射开关上转换纳米粒子（UCNPs）独立且精确地控制盐酸小檗碱（BBM）的释放和光敏剂的激活，以增强深层组织中的 PDT。首先，通过在 980nm 处激发 PB@UA 触发 BBM 的释放。BBM 可以抑制抗氧化酶的活性并破坏钙离子调节，使肿瘤细胞在随后的 PDT 治疗中更容易受到 ROS 诱导的细胞死亡。通过在 808nm 处辐照 PB@UA 上的 ZnPc 光敏剂启动 PDT，体内肿瘤抑制率达到 80.91%，明显高于单独 PDT（31.78%）或 BBM（11.29%）治疗，证明了我们的策略在改善癌症治疗方面的潜力。
